- AU$223.99m
- AU$210.27m
- AU$0.59m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.96 | ||
| Price to Tang. Book | 12.81 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 252.93 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -54.69% | ||
| Return on Equity | -43.67% | ||
| Operating Margin | -1261.85% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.02 | 0.01 | 0.02 | 0.05 | 0.59 | n/a | n/a | 93.78% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Race Oncology Limited is an Australia-based precision oncology company with a Phase II/III cancer drug called Zantrene. Zantrene is a potent small molecule inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. The Company is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers. Zantrene (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and a cardio-protective chemotherapeutic. The Company also has clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in acute myeloid leukemia (AML), breast and ovarian cancers and is investigating its use in these areas.
Directors
- John Cullity NEC
- Phillip Lynch CEO
- Christina Manfre CFO
- Daniel Tillett CSO
- Borje Andersson OTH
- David Fuller OTH (51)
- Peter Webse SEC
- Mary Harney NID
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 15th, 2011
- Public Since
- July 13th, 2016
- No. of Shareholders
- 8,524
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 163,496,251
- Address
- Level 36, Gateway 1, Macquarie Place, SYDNEY, 2000
- Web
- https://www.raceoncology.com/
- Phone
- +61 280513043
- Auditors
- Hall Chadwick WA Audit Pty Ltd
Upcoming Events for RAC
Similar to RAC
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Race Oncology share price?
As of Today at 19:17 UTC, shares in Race Oncology are trading at AU$1.37. This share price information is delayed by 15 minutes.
How has the Race Oncology share price performed this year?
Shares in Race Oncology last closed at AU$1.37 and the price had moved by -28.08% over the past 365 days. In terms of relative price strength the Race Oncology share price has underperformed the ASX All Ordinaries Index by -31.21% over the past year.
What are the analyst and broker recommendations for Race Oncology?
There is no consensus recommendation for this security.
What is the Race Oncology dividend yield?
Race Oncology does not currently pay a dividend.
Does Race Oncology pay a dividend?
Race Oncology does not currently pay a dividend.
When does Race Oncology next pay dividends?
Race Oncology does not currently pay a dividend.
How do I buy Race Oncology shares?
To buy shares in Race Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Race Oncology?
As of the previous close price of AU$1.37, shares in Race Oncology had a market capitalisation of AU$223.99m.
Where are Race Oncology shares listed?
Here are the trading details for Race Oncology:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: RAC
What kind of share is Race Oncology?
Based on an overall assessment of its quality, value and momentum Race Oncology is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Race Oncology share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Race Oncology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Race Oncology. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +40.15%.
As of the last closing price of AU$1.37, shares in Race Oncology were trading +35.86% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Race Oncology PE Ratio?
The Race Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$1.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Race Oncology?
Race Oncology's management team is headed by:
- John Cullity - NEC
- Phillip Lynch - CEO
- Christina Manfre - CFO
- Daniel Tillett - CSO
- Borje Andersson - OTH
- David Fuller - OTH
- Peter Webse - SEC
- Mary Harney - NID